Stockreport

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]

ZyVersa Therapeutics, Inc.  (ZVSA) 
PDF proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammat [Read more]